Rivaroxaban Monotherapy in Atrial Fibrillation and Stable Coronary Artery Disease Across Body Mass Index Categories.

ABSTRACT:

Background

The AFIRE (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease) trial showed both noninferiority for efficacy and superiority for safety endpoints of rivaroxaban monotherapy compared with those of rivaroxaban plus antiplatelet therapy (combination therapy) in patients with atrial fibrillation and stable coronary artery disease.

Objectives

This study sought to evaluate outcomes of rivaroxaban monotherapy in those patients across body mass index (BMI) categories.

Methods

Patients were categorized into 4 groups: underweight (BMI <18.5 kg/m²), normal weight (BMI 18.5 to <25 kg/m²), overweight (BMI 25 to <30 kg/m²), and obesity (BMI ≥30 kg/m²). Efficacy (a composite

SUBMITTER: Ishii M 

PROVIDER: S-EPMC9876995 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature